<p>Candel Therapeutics, Inc. (NASDAQ:CADL - 获取免费报告) 在覆盖该股票的八家评级公司中被赋予了 “适度买入” 的平均推荐，MarketBeat 报道。一位研究分析师对该股票给予了卖出评级，一位给予了持有评级，五位给予了买入评级，还有一位给予了强烈买入评级。在过去一年中，发布报告的分析师对该股票的平均 12 个月目标价为$18.3333。</p>
<p>获取 <strong>Candel Therapeutics</strong> 警报：</p>
<ul>
<li>异常高的交易量指向这些股票的上涨潜力</li>
</ul>
<p>CADL 最近成为几份研究报告的主题。HC Wainwright 在 9 月 29 日的研究报告中重申了对 Candel Therapeutics 的 “买入” 评级，并设定了$23.00 的目标价。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Candel Therapeutics 的 “卖出 (d-)” 评级。花旗集团在 11 月 14 日的报告中将 Candel Therapeutics 的目标价从$25.00 下调至$24.00，并对该公司设定了 “买入” 评级。Lifesci Capital 在 10 月 21 日的报告中开始覆盖 Candel Therapeutics。他们对该股票设定了 “跑赢大盘” 评级和$16.00 的价格目标。最后，华尔街禅在 11 月 15 日的研究报告中将 Candel Therapeutics 的评级从 “持有” 下调至 “卖出”。</p>
<p><strong>查看我们关于 CADL 的最新研究报告</strong></p>
<h2>Candel Therapeutics 的机构交易</h2>
<p>对该公司的对冲基金最近增加或减少了其持股。Acorn Capital Advisors LLC 在第二季度将其在 Candel Therapeutics 的持股增加了 19.9%。Acorn Capital Advisors LLC 现在拥有 2580517 股该公司的股票，价值 13057000 美元，在上个季度额外购买了 428265 股。先锋集团在第三季度将其在 Candel Therapeutics 的持股增加了 12.3%。先锋集团现在拥有 2007112 股该公司的股票，价值 10236000 美元，在上个季度额外购买了 219563 股。Geode Capital Management LLC 在第二季度将其在 Candel Therapeutics 的持股增加了 31.5%。Geode Capital Management LLC 现在拥有 903970 股该公司的股票，价值 4575000 美元，在上个季度额外购买了 216509 股。Halter Ferguson Financial Inc. 在第二季度将其在 Candel Therapeutics 的持股增加了 12.0%。Halter Ferguson Financial Inc. 现在拥有 776516 股该公司的股票，价值 3929000 美元，在上个季度额外购买了 83363 股。最后，Tanager Wealth Management LLP 在第二季度获得了 Candel Therapeutics 的新头寸，价值 995000 美元。机构投资者和对冲基金持有该公司 13.93% 的股票。</p>
<h2>Candel Therapeutics 股票表现</h2>
<p>Candel Therapeutics 股票在周五开盘价为$5.65。该股票的市值为 3.1019 亿美元，市盈率为-9.91，贝塔值为-0.94。该公司的债务与股本比率为 0.01，流动比率为 8.25，速动比率为 8.25。该业务的 50 日移动平均线为$5.27，200 日移动平均线为$5.52。Candel Therapeutics 的 12 个月低点为$4.25，12 个月高点为$13.68。</p>
<p>Candel Therapeutics (NASDAQ:CADL - 获取免费报告) 最近在 11 月 13 日发布了季度财报。该公司报告每股收益（EPS）为 ($0.21)，低于分析师共识预期的 ($0.17) $0.04。作为一个整体，卖方分析师预测 Candel Therapeutics 在本年度将发布-1.47 的每股收益。</p>
<h2>关于 Candel Therapeutics</h2>
<p>(获取免费报告)</p>
<p>Candel Therapeutics NASDAQ: CADL 是一家临床阶段的免疫肿瘤学公司，专注于开发下一代溶瘤病毒疗法，旨在治疗实体肿瘤。该公司的主要候选药物 CAN-2409 是一种局部给药的基因递送病毒疗法，旨在选择性地在癌细胞中复制并诱导免疫原性细胞死亡。Candel 利用专有的病毒工程平台来增强肿瘤特异性复制并刺激抗肿瘤免疫反应，旨在改善高未满足医疗需求患者的治疗效果。</p>
<p>除了其主要项目外，Candel 的管线还包括 CAN-3110，一种针对复发性高等级胶质瘤的溶瘤单纯疱疹病毒，以及其他正在探索的针对各种实体肿瘤适应症的新型病毒构建体。</p>
<h2>另见</h2>
<ul>
<li>五只我们认为比 Candel Therapeutics 更好的股票</li>
<li>黄金警报</li>
<li>如果你在美国银行账户中存现金……请立即阅读此内容</li>
<li>没有人告诉你的 100 万亿美元的人工智能故事</li>
<li>关于中国的震撼揭露</li>
<li>请勿删除，立即阅读</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0FETA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0FETA"/></p>
<p><em>此即时新闻警报由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Candel Therapeutics 吗？</h2>
<p>在你考虑 Candel Therapeutics 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 Candel Therapeutics 并不在名单上。</p>
<p>虽然 Candel Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

CADL

<p>Candel Therapeutics, Inc.（纳斯达克代码：CADL）获得了八家券商的 “适度买入” 共识评级。该股票有一个卖出评级、一个持有评级、五个买入评级和一个强烈买入评级。12 个月的平均目标价格为 18.33 美元。最近的报告包括 HC Wainwright 重申的买入评级，目标价为 23 美元，以及花旗集团下调的目标价。Candel 的股票开盘价为 5.65 美元，市值为 3.1019 亿美元。该公司报告的季度每股收益为（0.21 美元），未达到预期。Candel 专注于开发针对实体肿瘤的溶瘤病毒疗法</p>

<p>Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) has been assigned an average recommendation of &#34;Moderate Buy&#34; from the eight ratings firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $18.3333.</p>
<div class="lb-trans"><p>Candel Therapeutics, Inc. (NASDAQ:CADL - 获取免费报告) 在覆盖该股票的八家评级公司中被赋予了 “适度买入” 的平均推荐，MarketBeat 报道。一位研究分析师对该股票给予了卖出评级，一位给予了持有评级，五位给予了买入评级，还有一位给予了强烈买入评级。在过去一年中，发布报告的分析师对该股票的平均 12 个月目标价为$18.3333。</p>
</div><p>Get <strong>Candel Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Candel Therapeutics</strong> 警报：</p>
</div><ul>
<li>Unusually High Volume Points to Upside in These Stocks</li>
</ul>
<div class="lb-trans"><ul>
<li>异常高的交易量指向这些股票的上涨潜力</li>
</ul>
</div><p>CADL has been the topic of several recent research reports. HC Wainwright reaffirmed a &#34;buy&#34; rating and set a $23.00 target price on shares of Candel Therapeutics in a research note on Monday, September 29th. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Candel Therapeutics in a research note on Wednesday, October 8th. Citigroup decreased their target price on Candel Therapeutics from $25.00 to $24.00 and set a &#34;buy&#34; rating for the company in a report on Friday, November 14th. Lifesci Capital initiated coverage on Candel Therapeutics in a report on Tuesday, October 21st. They set an &#34;outperform&#34; rating and a $16.00 price target on the stock. Finally, Wall Street Zen lowered Candel Therapeutics from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Saturday, November 15th.</p>
<div class="lb-trans"><p>CADL 最近成为几份研究报告的主题。HC Wainwright 在 9 月 29 日的研究报告中重申了对 Candel Therapeutics 的 “买入” 评级，并设定了$23.00 的目标价。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Candel Therapeutics 的 “卖出 (d-)” 评级。花旗集团在 11 月 14 日的报告中将 Candel Therapeutics 的目标价从$25.00 下调至$24.00，并对该公司设定了 “买入” 评级。Lifesci Capital 在 10 月 21 日的报告中开始覆盖 Candel Therapeutics。他们对该股票设定了 “跑赢大盘” 评级和$16.00 的价格目标。最后，华尔街禅在 11 月 15 日的研究报告中将 Candel Therapeutics 的评级从 “持有” 下调至 “卖出”。</p>
</div><p><strong>Check Out Our Latest Research Report on CADL</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 CADL 的最新研究报告</strong></p>
</div><h2>Institutional Trading of Candel Therapeutics</h2>
<div class="lb-trans"><h2>Candel Therapeutics 的机构交易</h2>
</div><p>Hedge funds have recently added to or reduced their stakes in the company. Acorn Capital Advisors LLC lifted its stake in Candel Therapeutics by 19.9% in the second quarter. Acorn Capital Advisors LLC now owns 2,580,517 shares of the company's stock worth $13,057,000 after acquiring an additional 428,265 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Candel Therapeutics by 12.3% in the 3rd quarter. Vanguard Group Inc. now owns 2,007,112 shares of the company's stock valued at $10,236,000 after purchasing an additional 219,563 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Candel Therapeutics by 31.5% during the 2nd quarter. Geode Capital Management LLC now owns 903,970 shares of the company's stock worth $4,575,000 after purchasing an additional 216,509 shares during the last quarter. Halter Ferguson Financial Inc. grew its stake in shares of Candel Therapeutics by 12.0% during the second quarter. Halter Ferguson Financial Inc. now owns 776,516 shares of the company's stock worth $3,929,000 after purchasing an additional 83,363 shares in the last quarter. Finally, Tanager Wealth Management LLP acquired a new position in shares of Candel Therapeutics during the second quarter worth $995,000. Institutional investors and hedge funds own 13.93% of the company's stock.</p>
<div class="lb-trans"><p>对该公司的对冲基金最近增加或减少了其持股。Acorn Capital Advisors LLC 在第二季度将其在 Candel Therapeutics 的持股增加了 19.9%。Acorn Capital Advisors LLC 现在拥有 2580517 股该公司的股票，价值 13057000 美元，在上个季度额外购买了 428265 股。先锋集团在第三季度将其在 Candel Therapeutics 的持股增加了 12.3%。先锋集团现在拥有 2007112 股该公司的股票，价值 10236000 美元，在上个季度额外购买了 219563 股。Geode Capital Management LLC 在第二季度将其在 Candel Therapeutics 的持股增加了 31.5%。Geode Capital Management LLC 现在拥有 903970 股该公司的股票，价值 4575000 美元，在上个季度额外购买了 216509 股。Halter Ferguson Financial Inc. 在第二季度将其在 Candel Therapeutics 的持股增加了 12.0%。Halter Ferguson Financial Inc. 现在拥有 776516 股该公司的股票，价值 3929000 美元，在上个季度额外购买了 83363 股。最后，Tanager Wealth Management LLP 在第二季度获得了 Candel Therapeutics 的新头寸，价值 995000 美元。机构投资者和对冲基金持有该公司 13.93% 的股票。</p>
</div><h2>Candel Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Candel Therapeutics 股票表现</h2>
</div><p>Shares of Candel Therapeutics stock opened at $5.65 on Friday. The stock has a market capitalization of $310.19 million, a price-to-earnings ratio of -9.91 and a beta of -0.94. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.25 and a quick ratio of 8.25. The business has a 50-day moving average of $5.27 and a 200 day moving average of $5.52. Candel Therapeutics has a 12 month low of $4.25 and a 12 month high of $13.68.</p>
<div class="lb-trans"><p>Candel Therapeutics 股票在周五开盘价为$5.65。该股票的市值为 3.1019 亿美元，市盈率为-9.91，贝塔值为-0.94。该公司的债务与股本比率为 0.01，流动比率为 8.25，速动比率为 8.25。该业务的 50 日移动平均线为$5.27，200 日移动平均线为$5.52。Candel Therapeutics 的 12 个月低点为$4.25，12 个月高点为$13.68。</p>
</div><p>Candel Therapeutics (NASDAQ:CADL - Get Free Report) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.04). As a group, sell-side analysts forecast that Candel Therapeutics will post -1.47 earnings per share for the current year.</p>
<div class="lb-trans"><p>Candel Therapeutics (NASDAQ:CADL - 获取免费报告) 最近在 11 月 13 日发布了季度财报。该公司报告每股收益（EPS）为 ($0.21)，低于分析师共识预期的 ($0.17) $0.04。作为一个整体，卖方分析师预测 Candel Therapeutics 在本年度将发布-1.47 的每股收益。</p>
</div><h2>About Candel Therapeutics</h2>
<div class="lb-trans"><h2>关于 Candel Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Candel Therapeutics NASDAQ: CADL is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company's lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.</p>
<div class="lb-trans"><p>Candel Therapeutics NASDAQ: CADL 是一家临床阶段的免疫肿瘤学公司，专注于开发下一代溶瘤病毒疗法，旨在治疗实体肿瘤。该公司的主要候选药物 CAN-2409 是一种局部给药的基因递送病毒疗法，旨在选择性地在癌细胞中复制并诱导免疫原性细胞死亡。Candel 利用专有的病毒工程平台来增强肿瘤特异性复制并刺激抗肿瘤免疫反应，旨在改善高未满足医疗需求患者的治疗效果。</p>
</div><p>In addition to its lead program, Candel's pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.</p>
<div class="lb-trans"><p>除了其主要项目外，Candel 的管线还包括 CAN-3110，一种针对复发性高等级胶质瘤的溶瘤单纯疱疹病毒，以及其他正在探索的针对各种实体肿瘤适应症的新型病毒构建体。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Candel Therapeutics</li>
<li>GOLD ALERT</li>
<li>If You Keep Cash In A U.S. Bank Account… Read This NOW</li>
<li>The $100 Trillion AI Story No One Is Telling You</li>
<li>Bombshell Exposé on China Strikes</li>
<li>Do not delete, read immediately</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比 Candel Therapeutics 更好的股票</li>
<li>黄金警报</li>
<li>如果你在美国银行账户中存现金……请立即阅读此内容</li>
<li>没有人告诉你的 100 万亿美元的人工智能故事</li>
<li>关于中国的震撼揭露</li>
<li>请勿删除，立即阅读</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0FETA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=CADL"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Candel Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Candel Therapeutics 吗？</h2>
</div><p>Before you consider Candel Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Candel Therapeutics 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Candel Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 Candel Therapeutics 并不在名单上。</p>
</div><p>While Candel Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Candel Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Candel Therapeutics, Inc. (NASDAQ:CADL) 被券商一致评为 “适度买入”